Cargando…
Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial
BACKGROUND: Intrauterine adhesions (IUA) are the most common cause of uterine infertility and are caused by endometrium fibrotic regeneration following severe damage to the endometrium. Although current stem cell treatment options using different types of autologous stem cells have exhibited some be...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042450/ https://www.ncbi.nlm.nih.gov/pubmed/29996892 http://dx.doi.org/10.1186/s13287-018-0904-3 |
_version_ | 1783339156831731712 |
---|---|
author | Cao, Yun Sun, Haixiang Zhu, Hui Zhu, Xianghong Tang, Xiaoqiu Yan, Guijun Wang, Jingmei Bai, Donghui Wang, Juan Wang, Liu Zhou, Qi Wang, Huiyan Dai, Chengyan Ding, Lijun Xu, Biyun Zhou, Yan Hao, Jie Dai, Jianwu Hu, Yali |
author_facet | Cao, Yun Sun, Haixiang Zhu, Hui Zhu, Xianghong Tang, Xiaoqiu Yan, Guijun Wang, Jingmei Bai, Donghui Wang, Juan Wang, Liu Zhou, Qi Wang, Huiyan Dai, Chengyan Ding, Lijun Xu, Biyun Zhou, Yan Hao, Jie Dai, Jianwu Hu, Yali |
author_sort | Cao, Yun |
collection | PubMed |
description | BACKGROUND: Intrauterine adhesions (IUA) are the most common cause of uterine infertility and are caused by endometrium fibrotic regeneration following severe damage to the endometrium. Although current stem cell treatment options using different types of autologous stem cells have exhibited some beneficial outcomes in IUA patients, the reported drawbacks include variable therapeutic efficacies, invasiveness and treatment unavailability. Therefore, the development of new therapeutic stem cell treatments is critical to improving clinical outcomes. METHODS: Twenty-six patients who suffered from infertility caused by recurrent IUA were enrolled in this prospective, non-controlled, phase I clinical trial with a 30-month follow-up. During the procedure, 1 × 10(7) umbilical cord-derived mesenchymal stromal cells (UC-MSCs), loaded onto a collagen scaffold, were transplanted into the uterine cavity following an adhesion separation procedure. Medical history, physical examination, endometrial thickness, intrauterine adhesion score and the biological molecules related to endometrial proliferation and differentiation were assessed both before and 3 months after cell therapy. RESULTS: No treatment-related serious adverse events were found. Three months after the operation, the average maximum endometrial thickness in patients increased, and the intrauterine adhesion score decreased compared to those before the treatment. A histological study showed the upregulation of ERα (estrogen receptor α), vimentin, Ki67 and vWF (von Willebrand factor) expression levels and the downregulation of ΔNP63 expression level, which indicates an improvement in endometrial proliferation, differentiation and neovascularization following treatment. DNA short tandem repeat (STR) analysis showed that the regenerated endometrium contained patient DNA only. By the end of the 30-month follow-up period, ten of the 26 patients had become pregnant, and eight of them had delivered live babies with no obvious birth defects and without placental complications, one patient in the third trimester of pregnancy, and one had a spontaneous abortion at 7 weeks. CONCLUSIONS: Transplanting clinical-grade UC-MSCs loaded onto a degradable collagen scaffold into the uterine cavity of patients with recurrent IUA following adhesiolysis surgery is a safety and effective therapeutic method. TRIAL REGISTRATION: Clinicaltrials.gov. NCT02313415, Registered December 6, 2014. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13287-018-0904-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6042450 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60424502018-07-13 Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial Cao, Yun Sun, Haixiang Zhu, Hui Zhu, Xianghong Tang, Xiaoqiu Yan, Guijun Wang, Jingmei Bai, Donghui Wang, Juan Wang, Liu Zhou, Qi Wang, Huiyan Dai, Chengyan Ding, Lijun Xu, Biyun Zhou, Yan Hao, Jie Dai, Jianwu Hu, Yali Stem Cell Res Ther Research BACKGROUND: Intrauterine adhesions (IUA) are the most common cause of uterine infertility and are caused by endometrium fibrotic regeneration following severe damage to the endometrium. Although current stem cell treatment options using different types of autologous stem cells have exhibited some beneficial outcomes in IUA patients, the reported drawbacks include variable therapeutic efficacies, invasiveness and treatment unavailability. Therefore, the development of new therapeutic stem cell treatments is critical to improving clinical outcomes. METHODS: Twenty-six patients who suffered from infertility caused by recurrent IUA were enrolled in this prospective, non-controlled, phase I clinical trial with a 30-month follow-up. During the procedure, 1 × 10(7) umbilical cord-derived mesenchymal stromal cells (UC-MSCs), loaded onto a collagen scaffold, were transplanted into the uterine cavity following an adhesion separation procedure. Medical history, physical examination, endometrial thickness, intrauterine adhesion score and the biological molecules related to endometrial proliferation and differentiation were assessed both before and 3 months after cell therapy. RESULTS: No treatment-related serious adverse events were found. Three months after the operation, the average maximum endometrial thickness in patients increased, and the intrauterine adhesion score decreased compared to those before the treatment. A histological study showed the upregulation of ERα (estrogen receptor α), vimentin, Ki67 and vWF (von Willebrand factor) expression levels and the downregulation of ΔNP63 expression level, which indicates an improvement in endometrial proliferation, differentiation and neovascularization following treatment. DNA short tandem repeat (STR) analysis showed that the regenerated endometrium contained patient DNA only. By the end of the 30-month follow-up period, ten of the 26 patients had become pregnant, and eight of them had delivered live babies with no obvious birth defects and without placental complications, one patient in the third trimester of pregnancy, and one had a spontaneous abortion at 7 weeks. CONCLUSIONS: Transplanting clinical-grade UC-MSCs loaded onto a degradable collagen scaffold into the uterine cavity of patients with recurrent IUA following adhesiolysis surgery is a safety and effective therapeutic method. TRIAL REGISTRATION: Clinicaltrials.gov. NCT02313415, Registered December 6, 2014. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13287-018-0904-3) contains supplementary material, which is available to authorized users. BioMed Central 2018-07-11 /pmc/articles/PMC6042450/ /pubmed/29996892 http://dx.doi.org/10.1186/s13287-018-0904-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Cao, Yun Sun, Haixiang Zhu, Hui Zhu, Xianghong Tang, Xiaoqiu Yan, Guijun Wang, Jingmei Bai, Donghui Wang, Juan Wang, Liu Zhou, Qi Wang, Huiyan Dai, Chengyan Ding, Lijun Xu, Biyun Zhou, Yan Hao, Jie Dai, Jianwu Hu, Yali Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial |
title | Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial |
title_full | Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial |
title_fullStr | Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial |
title_full_unstemmed | Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial |
title_short | Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial |
title_sort | allogeneic cell therapy using umbilical cord mscs on collagen scaffolds for patients with recurrent uterine adhesion: a phase i clinical trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042450/ https://www.ncbi.nlm.nih.gov/pubmed/29996892 http://dx.doi.org/10.1186/s13287-018-0904-3 |
work_keys_str_mv | AT caoyun allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial AT sunhaixiang allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial AT zhuhui allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial AT zhuxianghong allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial AT tangxiaoqiu allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial AT yanguijun allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial AT wangjingmei allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial AT baidonghui allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial AT wangjuan allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial AT wangliu allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial AT zhouqi allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial AT wanghuiyan allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial AT daichengyan allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial AT dinglijun allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial AT xubiyun allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial AT zhouyan allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial AT haojie allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial AT daijianwu allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial AT huyali allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial |